Originally published June 4 2005
Nicotine vaccine may be solution to smoking habit
by Mike Adams, the Health Ranger, NaturalNews Editor
A study released in Orlando, Florida offers hope for people addicted to smoking: A nicotine vaccine. In test groups, 60 percent of smokers who developed high levels of antibodies against nicotine quit smoking. Of those who developed lower levels of antibodies, one-third quit. Thirty percent of smokers developed high levels of antibodies. Dr. Jacques Cornuz, the researcher who led the study, is working on ways to intense the vaccine's effects. The concept of the vaccine is simple: Antibodies bind to the nicotine as it enters the bloodstream and decrease its pleasurable effects on the brain. Cornuz's vaccine offers few side effects and is one of many vaccine-like smoking cures that are currently in development.
- Only about one-third of people who received the vaccine achieved the highest levels of antibodies.
- Before the company can begin larger clinical trials, it must find ways "to intensify the immunization scheme" so that more people achieve the necessary antibody levels.
- Get original quality Mac memory for a fraction of what you'd expect to pay, plus free shipping.
- The world's 1.3 billion smokers soon might have a powerful new way to kick the habit -- a vaccine against nicotine.
- Nearly 60 percent of smokers who achieved high levels of antibodies against nicotine after receiving the vaccine stopped smoking completely for at least six months, according to a new study presented Saturday at a meeting of the American Society of Clinical Oncology in Orlando, Fla.
- About one-third of those who developed lower levels of antibodies stopped smoking, about the same fraction as those who received a placebo vaccine, according to Dr. Jacques Cornuz of Centre Hospitalier Universitaire Vaudois in Lausanne, Switzerland, who led the study.
- "The data clearly suggest that antibodies against nicotine are effective in helping people quit smoking," Cornuz said.
- Only about one-third of people who received the vaccine achieved the highest levels of antibodies.
- Before the company can begin larger clinical trials, Cornuz said, it must find ways "to intensify the immunization scheme" so that more people achieve the necessary antibody levels.
- That might mean more injections, he said, or higher levels of the immunizing agent in each dose.
- "The best way to help patients is to prevent them from getting cancer in the first place," he said.
- Vaccines potentially offer a biological approach to breaking the addiction.
All content posted on this site is commentary or opinion and is protected under Free Speech. Truth Publishing LLC takes sole responsibility for all content. Truth Publishing sells no hard products and earns no money from the recommendation of products. NaturalNews.com is presented for educational and commentary purposes only and should not be construed as professional advice from any licensed practitioner. Truth Publishing assumes no responsibility for the use or misuse of this material. For the full terms of usage of this material, visit www.NaturalNews.com/terms.shtml